 |
|
JAMA-EXPRESS
Effect of Maintenance Therapy With Varenicline on Smoking Cessation
A Randomized Controlled Trial
Serena Tonstad, MD, PhD;
Philip Tønnesen, MD, PhD;
Peter Hajek, PhD;
Kathryn E. Williams, PhD;
Clare B. Billing, MS;
Karen R. Reeves, MD; for the Varenicline Phase 3 Study Group
JAMA. 2006;296:64-71.
Context The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacological treatment for relapse prevention is insufficient.
Objective To determine whether smokers who quit after 12 weeks of treatment with varenicline, a selective  4 2 nicotinic acetylcholine receptor partial agonist, maintain greater continuous abstinence rates (defined as not a single "puff" of a cigarette) than placebo controls during an additional 12 weeks of treatment and until 52 weeks after treatment initiation.
Design, Setting, and Participants Randomized controlled trial conducted at multiple medical clinics in 7 countries with follow-up to 52 weeks after study baseline. Of 1927 cigarette smokers recruited between April 2003 and February 2004 and treated for 12 weeks with open-label varenicline titrated to 1 mg twice per day, 1236 (64.1%) did not smoke, use tobacco, or use nicotine replacement therapy during the last week of treatment and 62.8% (n = 1210) were randomized to additional treatment or placebo.
Intervention Participants were randomly assigned to receive either double-blind varenicline, 1 mg twice per day (n = 603), or placebo (n = 607) for an additional 12 weeks.
Main Outcome Measures Carbon monoxide–confirmed continued abstinence during weeks 13 to 24 and weeks 13 to 52 of the study.
Results The carbon monoxide–confirmed continuous abstinence rate was significantly higher for the varenicline group than for the placebo group for weeks 13 to 24 (70.5% vs 49.6%; odds ratio [OR], 2.48; 95% confidence interval [CI], 1.95-3.16; P<.001) as well as for weeks 13 to 52 (43.6% vs 36.9%; OR, 1.34; 95% CI, 1.06-1.69; P = .02). Adverse events reported in the open-label period were mostly mild; no difference in adverse events between varenicline and placebo was observed during the double-blind period.
Conclusions Smokers who achieved abstinence for at least 7 days at the end of 12 weeks of open-label varenicline treatment and were randomized to receive an additional 12 weeks of varenicline treatment showed significantly greater continuous abstinence in weeks 13 to 24 compared with placebo. This advantage was maintained through the nontreatment follow-up to week 52. Varenicline may be an efficacious, safe, and well-tolerated agent for maintaining abstinence from smoking.
Trial Registration clinicaltrials.gov Identifier: NCT00143286
Author Affiliations: Department of Preventive Cardiology, Ullevål University Hospital, and University of Oslo, Oslo, Norway (Dr Tonstad); Department of Pulmonary Medicine, University of Copenhagen, and Gentofte Hospital, Copenhagen, Denmark (Dr Tønnesen); Wolfson Institute of Preventive Medicine, Queen Mary, University of London, London, England (Dr Hajek); and Pfizer Global Research and Development, Groton, Conn (Drs Williams and Reeves and Mr Billing).
RELATED ARTICLES
Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
David Gonzales, Stephen I. Rennard, Mitchell Nides, Cheryl Oncken, Salomon Azoulay, Clare B. Billing, Eric J. Watsky, Jason Gong, Kathryn E. Williams, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):47-55.
ABSTRACT
| FULL TEXT
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial
Douglas E. Jorenby, J. Taylor Hays, Nancy A. Rigotti, Salomon Azoulay, Eric J. Watsky, Kathryn E. Williams, Clare B. Billing, Jason Gong, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):56-63.
ABSTRACT
| FULL TEXT
Varenicline for Smoking Cessation: Definite Promise, But No Panacea
Robert C. Klesges, Karen C. Johnson, and Grant Somes
JAMA. 2006;296(1):94-95.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Varenicline for Tobacco Dependence
Hays and Ebbert
NEJM 2008;359:2018-2024.
FULL TEXT
Review: Pharmacotherapy for smoking cessation
Carrozzi et al.
Therapeutic Advances in Respiratory Disease 2008;2:301-317.
ABSTRACT
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
Pirmoradi et al.
Am J Health Syst Pharm 2008;65:1624-1626.
ABSTRACT
| FULL TEXT
Smoking: A Deadly Pleasant Habit--Is There a Way Out?
Richter
ANGIOLOGY 2008;59:49S-53S.
ABSTRACT
Diffuse exanthema in a patient receiving varenicline
Song and Miller
Am J Health Syst Pharm 2008;65:1239-1241.
ABSTRACT
| FULL TEXT
{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT
| FULL TEXT
Hypomania with Agitation Associated with Varenicline Use in Bipolar II Disorder
Morstad et al.
The Annals of Pharmacotherapy 2008;42:288-289.
FULL TEXT
The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline
Hollis et al.
Tobacco Control 2007;16:i53-i59.
ABSTRACT
| FULL TEXT
Treatment of tobacco dependence: integrating recent progress into practice
Le Foll and George
CMAJ 2007;177:1373-1380.
ABSTRACT
| FULL TEXT
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow et al.
Arch Neurol 2007;64:1575-1579.
ABSTRACT
| FULL TEXT
Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
Bailey and Tashkin
Proc Am Thorac Soc 2007;4:543-548.
ABSTRACT
| FULL TEXT
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Rabe et al.
Am. J. Respir. Crit. Care Med. 2007;176:532-555.
ABSTRACT
| FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT
Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
Steensland et al.
Proc. Natl. Acad. Sci. USA 2007;104:12518-12523.
ABSTRACT
| FULL TEXT
Update in General Internal Medicine
Harrington and Munekata
ANN INTERN MED 2007;147:104-116.
FULL TEXT
Varenicline: The newest agent for smoking cessation
Potts and Garwood
Am J Health Syst Pharm 2007;64:1381-1384.
ABSTRACT
| FULL TEXT
Expression of Nicotinic Acetylcholine Receptor Subunit Genes in Non-Small-Cell Lung Cancer Reveals Differences between Smokers and Nonsmokers
Lam et al.
Cancer Res. 2007;67:4638-4647.
ABSTRACT
| FULL TEXT
State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
Sullivan et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:201-213.
ABSTRACT
Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review
Leeman et al.
Alcohol Alcohol 2007;42:196-206.
ABSTRACT
| FULL TEXT
Update in Lung Cancer 2006
Dubey and Powell
Am. J. Respir. Crit. Care Med. 2007;175:868-874.
FULL TEXT
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy
Tonnesen et al.
Eur Respir J 2007;29:390-417.
ABSTRACT
| FULL TEXT
Et al
Evid. Based Ment. Health 2007;10:7-8.
FULL TEXT
Guideline Watch (April 2007): Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Edition
Connery and Kleber
Focus 2007;5:163-166.
ABSTRACT
| FULL TEXT
Varenicline (Chantix) for Tobacco Dependence
Obstet Gynecol 2007;109:192-193.
FULL TEXT
Oral Varenicline for Smoking Cessation
Zierler-Brown and Kyle
The Annals of Pharmacotherapy 2007;41:95-99.
ABSTRACT
| FULL TEXT
Efficacy of Varenicline for Smoking Cessation
Dervaux et al.
JAMA 2006;296:2555-2555.
FULL TEXT
Evidently...
Lehman
Evid. Based Med. 2006;11:167-167.
FULL TEXT
Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit.
Schroeder and Sox
ANN INTERN MED 2006;145:784-785.
FULL TEXT
Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT
Is a New Smoking-Cessation Drug on the Horizon?
Journal Watch Cardiology 2006;2006:5-5.
FULL TEXT
New Drug for Smoking Cessation
JWatch General 2006;2006:2-2.
FULL TEXT
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales et al.
JAMA 2006;296:47-55.
ABSTRACT
| FULL TEXT
Varenicline for smoking cessation: definite promise, but no panacea.
Klesges et al.
JAMA 2006;296:94-95.
FULL TEXT
|
